title: Quantitative determinations of anti-Kaposi sarcoma-associated herpesvirus antibody levels in men who have sex with men.
abstract: Infection with Kaposi sarcoma-associated herpesvirus (KSHV; also called human herpesvirus-8) is common among men who have sex with men (MSM). Here, quantitative anti-KSHV antibody levels were measured using luciferase immunoprecipitation systems (LIPS) in an MSM cohort with and without HIV from the NIH Clinical Center. Antibodies were detected using a mixture of 4 KSHV antigens in the MSM cohort and in Kaposi sarcoma (KS) patients. Along with HIV status, these results were compared with K8.1 and ORF73 ELISA, PCR virus detection, and additional LIPS testing. LIPS revealed that 25% (76/307) of the MSM cohort were KSHV seropositive, including 59 HIV+ and 17 HIV- subjects. The anti-KSHV antibody levels detected by LIPS were not statistically different between the KSHV+/HIV+ and KSHV+/HIV- subgroups but were lower than the KS patients (P < 0.0001). ELISA analysis of the MSM cohort detected a 35.5% frequency of KSHV infection and showed agreement with 81% of the samples evaluated by LIPS. Further LIPS testing with v-cyclin, a second ORF73 fragment and ORF38 reconciled some of the differences observed between LIPS and the ELISA immunoassays, and the revised LIPS seroprevalence in the MSM cohort was increased to 31%. Additional quantitative antibody analysis demonstrated statistically lower KSHV antibody levels in MSM compared to KS patients, but no difference was found between KSHV infected with and without HIV coinfection. These findings also suggest that antibodies against v-cyclin and ORF38 are useful for identifying patients with asymptomatic KSHV infection.
authors.affiliation: Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Emile
authors.initials: E
authors.lastname: Gogineni
authors.forename: Vickie
authors.initials: V
authors.lastname: Marshall
authors.forename: Wendell
authors.initials: W
authors.lastname: Miley
authors.forename: Ahmad
authors.initials: A
authors.lastname: Bayat
authors.forename: Denise
authors.initials: D
authors.lastname: Whitby
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Kovacs
authors.forename: Peter D
authors.initials: PD
authors.lastname: Burbelo
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D000956:Antigens, Viral / Q000097:blood*; D015331:Cohort Studies; D004797:Enzyme-Linked Immunosorbent Assay; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis / Q000821:virology; D019288:Herpesvirus 8, Human / Q000276:immunology*; D018451:Homosexuality, Male; D006801:Humans; D047468:Immunoprecipitation; D008297:Male; D016133:Polymerase Chain Reaction; D012514:Sarcoma, Kaposi / Q000150:complications / Q000175:diagnosis* / Q000821:virology; D016036:Seroepidemiologic Studies
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral
references.citation: J Vis Exp. 2009 Oct 07;(32):
references.pmid: 19812534
references.citation: Curr Opin Infect Dis. 2011 Aug;24(4):295-301
references.pmid: 21666458
references.citation: PLoS One. 2009 May 19;4(5):e5613
references.pmid: 19479040
references.citation: Sex Transm Infect. 2006 Jun;82(3):229-35
references.pmid: 16731675
references.citation: Clin Vaccine Immunol. 2009 May;16(5):621-7
references.pmid: 19261774
references.citation: J Infect Dis. 2011 Dec 1;204(11):1683-91
references.pmid: 21990424
references.citation: Clin Infect Dis. 2010 Aug 1;51(3):350-8
references.pmid: 20583924
references.citation: J Infect Dis. 2010 Jun 15;201(12):1919-22
references.pmid: 20443737
references.citation: J Immunol Methods. 2010 Apr 30;356(1-2):39-46
references.pmid: 20211626
references.citation: J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):557-62
references.pmid: 18989224
references.citation: J Clin Microbiol. 2006 Oct;44(10):3734-41
references.pmid: 17021103
references.citation: N Engl J Med. 2000 Nov 9;343(19):1369-77
references.pmid: 11070101
references.citation: J Virol Methods. 2001 Feb;91(2):109-17
references.pmid: 11164492
references.citation: Clin Immunol. 2007 Nov;125(2):120-6
references.pmid: 17904423
references.citation: J Clin Virol. 2006 Apr;35(4):442-9
references.pmid: 16414306
references.citation: BMC Infect Dis. 2007 Dec 05;7:143
references.pmid: 18053246
references.citation: Int J Cancer. 2007 Jan 15;120(2):321-8
references.pmid: 17066452
references.citation: J Infect Dis. 2003 Jan 1;187(1):12-8
references.pmid: 12508141
references.citation: N Engl J Med. 1998 Apr 2;338(14):948-54
references.pmid: 9521982
references.citation: J Infect Dis. 2002 Apr 1;185(7):990-3
references.pmid: 11920325
references.citation: J Infect Dis. 2007 Jul 15;196(2):199-207
references.pmid: 17570106
references.citation: Nat Rev Cancer. 2010 Oct;10(10):707-19
references.pmid: 20865011